Fintel reports that on January 31, 2025, Canaccord Genuity downgraded their outlook for Intra-Cellular Therapies ...

Shares of Intra-Cellular Therapies are surging 35% in premarket trading Monday after Johnson & Johnson said it will acquire ...

Intra-Cellular Therapies, Inc., a biopharmaceutical company, focuses on the discovery, clinical development, and commercialization of small molecule drugs that address medical needs primarily in ...

Canaccord Genuity analysts downgraded Intra-Cellular Therapies (NASDAQ:ITCI) stock from Buy to Hold, adjusting the price target to $132 from the previous $119. The revision follows the recent ...

In a report released on January 27, Jessica Fye from J.P. Morgan maintained a Buy rating on Intra-Cellular Therapies (ITCI – Research Report), ...

Johnson & Johnson has announced its acquisition of Intra-Cellular Therapies for approximately $14.6 billion, paying $132 per share in cash. The acquisition includes CAPLYTA® (lumateperone), the ...

In this article, we are going to take a look at where Intra-Cellular Therapies (NASDAQ:ITCI) stands against the other stocks. Stock gains always get people talking, and 2025 is no exception.

Investment analysts at StockNews.com assumed coverage on shares of Intra-Cellular Therapies (NASDAQ:ITCI – Get Free Report) in a research report issued to clients and investors on Thursday.

In the preceding three months, 6 analysts have released ratings for Intra-Cellular Therapies ITCI, presenting a wide array of perspectives from bullish to bearish. The table below provides a ...

We sell different types of products and services to both investment professionals and individual investors. These products and services are usually sold through license agreements or subscriptions ...

We recently compiled a list of the Why These 15 Stocks Are Skyrocketing in 2025. In this article, we are going to take a look at where Intra-Cellular Therapies (NASDAQ:ITCI) stands against the other ...